Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864100 | 0.83 | NPSR1 (0.48) | L3MBTL1NPSR1PPARACTSSMAOB | |
| SCHEMBL214081 | 0.83 | NPSR1 (0.43) | L3MBTL1NPSR1PPARACTSSMAOB | |
| SCHEMBL214082 | 0.83 | NPSR1 (0.43) | L3MBTL1NPSR1PPARACTSSMAOB | |
| SCHEMBL210654 | 0.82 | L3MBTL1 (0.50) | L3MBTL1NPSR1PPARACTSSMAOB | |
| SCHEMBL210653 | 0.82 | L3MBTL1 (0.50) | L3MBTL1NPSR1PPARACTSSMAOB | |
| SCHEMBL4859584 | 0.81 | NPSR1 (0.47) | L3MBTL1NPSR1PPARACTSSMAOB | |
| SCHEMBL4860811 | 0.78 | NPSR1 (0.44) | L3MBTL1NPSR1PPARACTSSMAOB | |
| SCHEMBL22087770 | 0.78 | NPSR1 (0.44) | L3MBTL1NPSR1PPARACTSSMAOB | |
| SCHEMBL1374797 | 0.77 | PPARA (0.52) | L3MBTL1NPSR1PPARACTSSMAOB | |
| SCHEMBL1374794 | 0.77 | PPARA (0.52) | L3MBTL1NPSR1PPARACTSSMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | L3MBTL1 4642/4885NPSR1 3598/4885PPARA 1285/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | L3MBTL1 4642/4885NPSR1 3598/4885PPARA 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.